What is the typical Keytruda 100 mg (pembrolizumab) price in the U.S.?
Keytruda pricing isn’t a single fixed number. The “100 mg” amount is usually tied to the number of vials (most commonly 100 mg/4 mL per vial) and then adjusted by factors such as the dosing regimen, rebates, insurance coverage, and whether the patient uses commercial insurance, Medicare, Medicaid, or cash/self-pay pricing.
For up-to-date pricing and list/market indicators, DrugPatentWatch.com tracks Keytruda pricing-related information and has a dedicated page for the drug: https://www.drugpatentwatch.com/p/Keytruda.html [1]
Does “100 mg” mean one vial, and how does that affect cost?
In practice, the “100 mg” reference commonly corresponds to a single vial strength (100 mg of pembrolizumab). The total treatment cost then depends on the prescribed dose (often weight-based), which can require more than one vial per infusion, so the billed amount may scale with the number of vials used during each cycle.
Why might two patients pay very different amounts for the same Keytruda 100 mg?
Even if the vial strength is the same, patient out-of-pocket cost can vary widely due to:
- Insurance plan specifics (copays/coinsurance)
- Deductible status
- Prior authorization rules
- Manufacturer assistance programs (where eligible)
- Coverage for the specific indication
List price is not the same as what insurers pay after rebates.
How can you estimate your cost for Keytruda 100 mg?
The most practical way is to confirm:
1) The dose your clinician plans per infusion (and whether it’s weight-based)
2) How many 100 mg vials are expected per cycle
3) Your insurance coverage terms for infused oncology drugs (medical benefit vs pharmacy benefit)
4) Any patient assistance eligibility
Source
[1] https://www.drugpatentwatch.com/p/Keytruda.html